Known targets — ChEMBL curated mechanism
PDE4APDE4BPDE4CPDE4DPDE7APDE7BPDE8APDE8B
The experimentally established mechanism targets of Flavoxate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | HTR1A | P08908 | 3/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | ACHE | P22303 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flavoxate SCHEMBL29395220 | 1.00 | LMNA (0.98) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL29421720 | 0.99 | LMNA (1.00) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL25801 | 0.99 | LMNA (1.00) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL1650335 | 0.97 | LMNA (0.96) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL7061192 | 0.94 | LMNA (0.90) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10549683 | 0.93 | LMNA (0.85) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL11035366 | 0.92 | LMNA (0.83) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10709825 | 0.92 | LMNA (0.83) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| SCHEMBL10707910 | 0.91 | LMNA (0.84) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10710690 | 0.90 | LMNA (0.80) | LMNAHTR1AADRA1AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2318 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025062440-A1 | TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF | PULSE PHARMACEUTICALS PVT. LTD (IN) | 2025-03-27 | — | — | WO | claimed |
| US-11992558-B2 | Controlled release formulation comprising flavoxate | BERLIA, Sushma Paul (IN) | 2024-05-28 | — | — | US | claimed |
| US-20230330076-A1 | CONTROLLED RELEASE FORMULATIONS OF FLAVOXATE AND PROCESS FOR PREPARATION THEREOF | FLAVOSTAR LLC | 2023-10-19 | — | — | US | claimed |
| WO-2023089553-A1 | CONTROLLED RELEASE FORMULATIONS OF FLAVOXATE AND PROCESS FOR PREPARATION THEREOF | BERLIA SUSHMA PAUL (IN) | 2023-05-25 | — | — | WO | claimed |
| CN-115960065-A | Preparation method of flavoxate hydrochloride | 山东鲁西药业有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-20210299053-A1 | CONTROLLED RELEASE FORMULATION COMPRISING FLAVOXATE | SUSHMA PAUL BERLIA (IN) | 2021-09-30 | — | — | US | claimed |
| EP-3823600-A1 | CONTROLLED RELEASE FORMULATION COMPRISING FLAVOXATE | BERLIA, Sushma Paul (IN) | 2021-05-26 | — | — | EP | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112654366-A | Methods of treating or inhibiting the onset of huntington's disease | 罗切斯特大学 | 2021-04-13 | — | — | CN | claimed |
| CN-111153881-A | Preparation method for synthesizing intermediate 3-methylflavone-8-carboxylic acid of flavoxate hydrochloride | 辽宁海德制药有限公司 | 2020-05-15 | — | — | CN | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1457490-A1 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20030018061-A1 | Novel remedies with the use of beta 3 agonist | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-01-23 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-1258253-A1 | NOVEL REMEDIES WITH THE USE OF BETA3 AGONIST | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-20 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5165937-A | Urinary disorders | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1992-11-24 | — | — | US | claimed |
| WO-1992015305-A1 | METHOD OF TREATMENT FOR ASTHMA, BRONCHOSPASM AND OBSTRUCTIVE LUNG DISEASE | BAKER CUMMINS PHARMACEUTICALS, INC. (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0393572-A2 | Controlled release tablets containing flavoxate | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1990-10-24 | — | — | EP | claimed |